Karolinska Institutet hereby invites you to submit a tender for a Multifactorial Test for Prostate Cancer Diagnostics. The test is a blood test that should include clinical information, protein levels
and a genetic test.
A form of study to produce observational so-called "real world data" that can demonstrate whether the results from the randomized trials stand up to the actual screening situation in the population.
Invitation to tender
Karolinska Institutet hereby invites you to submit a tender for a Multifactorial Test for Prostate Cancer Diagnostics. The test is a blood test that should include clinical information, protein levels, and a genetic test.
Karolinska Institutet hereby invites you to submit a tender for a Multifactorial Test for Prostate Cancer Diagnostics. The test is a blood test that should include clinical information, protein levels
and a genetic test.
A form of study to produce observational so-called "real world data" that can demonstrate whether the results from the randomized trials stand up to the actual screening situation in the population.
Invitation to tender
Karolinska Institutet hereby invites you to submit a tender for a Multifactorial Test for Prostate Cancer Diagnostics. The test is a blood test that should include clinical information, protein levels, and a genetic test.
About Karolinska Institutet
Karolinska Institutet, hereinafter referred to as KI, is one of the world's leading medical universities. Our vision is to make a decisive contribution to improving people's health. Our mission is to conduct research and education and to collaborate with the surrounding community.
In Sweden, KI accounts for the single largest share of medical academic research and has the largest range of medical education.
Since 1901, the Nobel Assembly at Karolinska Institutet has appointed recipients of the Nobel Prize in Physiology or Medicine.
For more information, please see ki.se.
Extent
The National Board of Health and Welfare has commissioned the regions to create regional programmes for so-called organised prostate cancer testing (OPT). OPT means that men of a relevant age receive an invitation to participate in a screening program similar to breast cancer screening, but to detect prostate cancer. Today, OPT is carried out in Region Stockholm with a flow where all men in a selected age category are invited to be tested. Testing is carried out in three stages; blood tests with PSA tests, those with elevated values undergo magnetic resonance imaging (MRI) and those with abnormal areas on magnetic resonance imaging (MRI) undergo tissue samples. This algorithm poses major challenges on the capacity and resources for MRI use and the regions now wish to evaluate alternative ways to reduce the proportion of men who need to undergo MRI. There are multifactual tests where evidence shows that it is possible to safely reduce the use of MRI without reducing the likelihood of detecting cancer.
Within OPT in 2024, we will conduct a study where we plan to invite 27,000 men in the region aged 50 and 52 for prostate cancer diagnostics. Based on previous OPT years, we expect a participation of about 37% and thus about 10,000 participating men. In this group, we would expect 4%, i.e. 400 men, to undergo MRI. Using a multifactorial test, this would decrease about 35% according to the evidence, i.e. 140 MRI examinations less. This would have an important impact on the inconvenience the examination causes the men as well as from a resource point of view.
Scope of the test:
To achieve this reduction in MRI use, we estimate, based on previous studies, that 10% will have a limit value of PSA to undergo a multifactorial test, i.e. about 1,000 men.
The study has sent the application to the Ethical Review Board as well as a supplement that is under assessment.
KI intends to sign contracts with a (1) supplier if possible.